Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Sep 22, 2025 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, regulatory
TL;DR
Aptose Biosciences filed an 8-K on 9/22/25, check for financial updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on September 22, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is based in Toronto, Canada, and operates in the biological products sector.
Why It Matters
This filing indicates ongoing regulatory compliance and disclosure of financial information for Aptose Biosciences Inc., which is relevant for investors tracking the company's status.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, primarily containing disclosures and exhibits, without immediate significant financial events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- September 22, 2025 (date) — Date of Report
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc. (company) — Former Company Name
- Toronto, Canada (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing by Aptose Biosciences Inc.?
The filing is a Current Report (8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting under Regulation FD Disclosure and including Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The date of the report, and the date of the earliest event reported, is September 22, 2025.
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and prior to that, Imutec Pharma Inc.
Where is Aptose Biosciences Inc. located?
The company's business and mail address is located in Toronto, Canada.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-09-22 07:45:31
Filing Documents
- f8k_092225.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-25-005992.txt ( ) — 218KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_092225_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated September 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: September 22, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer